Julie Rubinstein - 27 Apr 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Reporting relationship: President and COO
Issuer ticker: ADPT
Reported as of: 27 Apr 2026
Net transaction value: -$270,897
SEC form: 4
Accepted by SEC: 29 Apr 2026, 19:08:52 UTC
Prior SEC filing: 24 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact

Key filing fact

Julie Rubinstein filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 29 Apr 2026.

Key facts

This page summarizes Julie Rubinstein's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Apr 2026, 19:08.

Change

Previous filing in this sequence was filed on 24 Apr 2026.
Current net transaction value: -$270,897.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001780664 Primary reporting owner

RUBINSTEIN JULIE

Relationship: President and COO
Address: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE
Signature: /s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact
Signature date: 29 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADPT transaction

Common Stock

Options Exercise

Transaction value
Shares: +14,707
Change %: +3.8%
Price: $8.46^*
Shares after: 396,839
Date: 27 Apr 2026
Ownership: Direct
Footnotes: F1

ADPT transaction

Common Stock

Sale

Transaction value: $270,897
Shares: -19,037
Change %: -4.8%
Price: $14.23
Shares after: 377,802
Date: 27 Apr 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADPT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -14,707
Change %: -24%
Price: $0.000000^*
Shares after: 45,731
Date: 27 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,707
Exercise price: $8.46
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

Footnote F2

The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.08 to $14.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Footnote F3

The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.